This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

A Preliminary Clinical Trial

Lawrence W. Myers, MD; John L. Fahey, MD; Dewey J. Moody, PhD; M. Ray Mickey, PhD; Margaret V. Frane; George W. Ellison, MD

Arch Neurol. 1987;44(8):828-832.

Abstract
• To our knowledge, this is the first clinical trial in multiple sclerosis (MS) demonstrating the feasibility of directing immunomodulating therapy by monitoring immunologic results. Cyclophosphamide was administered at monthly intervals, escalating the dose until there was a significant reduction in both the number of blood B lymphocytes and helper/inducer (CD4) T cells of 14 patients with chronic progressive MS. The frequency and severity of adverse effects led us to conclude that the regimen is too toxic for the long-term treatment of patients with MS.

Author Affiliations
From the Department of Neurology, Reed Neurological Research Center (Drs Myers and Ellison and Ms Frane), the Medical Immunology Laboratory, Center for Interdisciplinary Research and Immunologic Diseases, Department of Microbiology and Immunology (Drs Fahey and Moody), and the Department of Biostatistics (Dr Mickey), UCLA School of Medicine.

Footnotes
Accepted for publication April 3, 1987.

Reprint requests to Reed Neurological Research Center, 710 Westwood Plaza, Los Angeles, CA 90024 (Dr Myers).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Reduction of Disease Activity and Disability With High-Dose Cyclophosphamide in Patients With Aggressive Multiple Sclerosis
Krishnan et al.
Arch Neurol 2008;65:1044-1051.
ABSTRACT | FULL TEXT  

Safety and tolerability of cyclophosphamide 'pulses' in multiple sclerosis: a prospective study in a clinical cohort
Portaccio et al.
Mult Scler 2003;9:446-450.
ABSTRACT  

Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects
Weiner and Cohen
Mult Scler 2002;8:142-154.
ABSTRACT  

Combination of cyclophosphamide and interferon-{beta} halts progression in patients with rapidly transitional multiple sclerosis
Patti et al.
J. Neurol. Neurosurg. Psychiatry 2001;71:404-407.
ABSTRACT | FULL TEXT  

Treatment of progressive multiple sclerosis with pulse cyclophosphamidel methylprednisolone: Response to therapy is linked to the duration of progressive disease
Hohol et al.
Mult Scler 1999;5:403-409.
ABSTRACT